AbbVie Inc. Stock
€193.40
Your prediction
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | -1.930% | 5.625% | 13.099% | 16.086% | -1.527% | 51.449% | 109.580% |
| BioMarin Pharmaceutical Inc. | 0.670% | 3.678% | 6.863% | -1.308% | -3.635% | -43.018% | -24.212% |
| Biogen Inc. | -1.590% | 1.101% | 1.704% | 43.065% | 11.512% | -41.696% | -48.529% |
| Zoetis Inc. A | -0.700% | 2.490% | -2.816% | -54.202% | -36.345% | -55.157% | -52.210% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.
Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.
Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.
Comments
News
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
When it comes to major dividend growth stocks, many come to mind, particularly widely held consumer staples stocks. However, because of their popularity, many have arguably become stretched in terms
The Best Stocks to Invest $500 in Right Now
Some investors are avoiding the healthcare sector right now due to its lagging the market in recent years and its somewhat uncertain outlook. However, this bearish sentiment could mean there are
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
Despite its shares being in the red year to date, AbbVie's (NYSE: ABBV) financial results have been strong. The company's first-quarter update, released on April 29, came in ahead of expectations on